Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease (May 2024)

Trends in Dual Antiplatelet Therapy of Aspirin and Clopidogrel and Outcomes in Ischemic Stroke Patients Noneligible for POINT/CHANCE Trial Treatment

  • Joon‐Tae Kim,
  • Ji Sung Lee,
  • Hyunsoo Kim,
  • Beom Joon Kim,
  • Keon‐Joo Lee,
  • Jong‐Moo Park,
  • Kyusik Kang,
  • Soo Joo Lee,
  • Jae Guk Kim,
  • Jae‐Kwan Cha,
  • Dae‐Hyun Kim,
  • Tai Hwan Park,
  • Kyungbok Lee,
  • Jun Lee,
  • Keun‐Sik Hong,
  • Yong‐Jin Cho,
  • Hong‐Kyun Park,
  • Byung‐Chul Lee,
  • Kyung‐Ho Yu,
  • Mi Sun Oh,
  • Dong‐Eog Kim,
  • Jay Chol Choi,
  • Jee‐Hyun Kwon,
  • Wook‐Joo Kim,
  • Dong‐Ick Shin,
  • Kyu Sun Yum,
  • Sung Il Sohn,
  • Jeong‐Ho Hong,
  • Sang‐Hwa Lee,
  • Man‐Seok Park,
  • Wi‐Sun Ryu,
  • Kwang‐Yeol Park,
  • Juneyoung Lee,
  • Jeffrey L. Saver,
  • Hee‐Joon Bae

DOI
https://doi.org/10.1161/JAHA.123.033611
Journal volume & issue
Vol. 13, no. 10

Abstract

Read online

Background Recent clinical trials established the benefit of dual antiplatelet therapy with aspirin and clopidogrel (DAPT‐AC) in early‐presenting patients with minor ischemic stroke. However, the impact of these trials over time on the use and outcomes of DAPT‐AC among the patients with nonminor or late‐presenting stroke who do not meet the eligibility criteria of these trials has not been delineated. Methods and Results In a multicenter stroke registry, this study examined yearly changes from April 2008 to August 2022 in DAPT‐AC use for stroke patients ineligible for CHANCE/POINT (Clopidogrel in High‐Risk Patients with Acute Nondisabling Cerebrovascular Events/Platelet‐Oriented Inhibition in New TIA and Minor Ischemic Stroke) clinical trials due to National Institutes of Health Stroke Scale >4 or late arrival beyond 24 hours of onset. A total of 32 118 patients (age, 68.1±13.1 years; male, 58.5%) with National Institutes of Health Stroke Scale of 4 (interquartile range, 1–7) were analyzed. In 2008, DAPT‐AC was used in 33.0%, other antiplatelets in 62.7%, and no antiplatelet in 4.3%. The frequency of DAPT‐AC was relatively unchanged through 2013, when the CHANCE trial was published, and then increased steadily, reaching 78% in 2022, while other antiplatelets decreased to 17.8% in 2022 (Ptrend<0.001). From 2011 to 2022, clinical outcomes nonsignificantly improved, with an average relative risk reduction of 2%/y for the composite of stroke, myocardial infarction, and all‐cause mortality, both among patients treated with DAPT‐AC and patients treated with other antiplatelets. Conclusions Use of DAPT‐AC in stroke patients with stroke ineligible for recent DAPT clinical trials increased markedly and steadily after CHANCE publication in 2013, reaching deployment in nearly 4 of every 5 patients by 2022. The secondary prevention in patients with ischemic stroke seems to be gradually improving, possibly due to the enhancement of risk factor control.

Keywords